These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 26234760)

  • 21. The Gut-Liver Axis in Cholestatic Liver Diseases.
    Blesl A; Stadlbauer V
    Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801133
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of bile acids in the gut-liver axis.
    Schneider KM; Albers S; Trautwein C
    J Hepatol; 2018 May; 68(5):1083-1085. PubMed ID: 29519549
    [No Abstract]   [Full Text] [Related]  

  • 23. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity-Linked Gut Microbiome Dysbiosis Associated with Derangements in Gut Permeability and Intestinal Cellular Homeostasis Independent of Diet.
    Nagpal R; Newman TM; Wang S; Jain S; Lovato JF; Yadav H
    J Diabetes Res; 2018; 2018():3462092. PubMed ID: 30250849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery.
    Anhê FF; Varin TV; Schertzer JD; Marette A
    Can J Diabetes; 2017 Aug; 41(4):439-447. PubMed ID: 28552651
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation.
    van Best N; Jansen PL; Rensen SS
    Hepatol Int; 2015 Jul; 9(3):406-15. PubMed ID: 26067771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Local Defender and Functional Mediator: Gut Microbiome.
    Yang H; Duan Z
    Digestion; 2018; 97(2):137-145. PubMed ID: 29310114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging pathogenic links between microbiota and the gut-lung axis.
    Budden KF; Gellatly SL; Wood DL; Cooper MA; Morrison M; Hugenholtz P; Hansbro PM
    Nat Rev Microbiol; 2017 Jan; 15(1):55-63. PubMed ID: 27694885
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging.
    Perino A; Demagny H; Velazquez-Villegas L; Schoonjans K
    Physiol Rev; 2021 Apr; 101(2):683-731. PubMed ID: 32790577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The joint power of sex and stress to modulate brain-gut-microbiota axis and intestinal barrier homeostasis: implications for irritable bowel syndrome.
    Pigrau M; Rodiño-Janeiro BK; Casado-Bedmar M; Lobo B; Vicario M; Santos J; Alonso-Cotoner C
    Neurogastroenterol Motil; 2016 Apr; 28(4):463-86. PubMed ID: 26556786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prebiotic effects: metabolic and health benefits.
    Roberfroid M; Gibson GR; Hoyles L; McCartney AL; Rastall R; Rowland I; Wolvers D; Watzl B; Szajewska H; Stahl B; Guarner F; Respondek F; Whelan K; Coxam V; Davicco MJ; Léotoing L; Wittrant Y; Delzenne NM; Cani PD; Neyrinck AM; Meheust A
    Br J Nutr; 2010 Aug; 104 Suppl 2():S1-63. PubMed ID: 20920376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gut microbiome as a therapeutic target for liver diseases.
    Singh TP; Kadyan S; Devi H; Park G; Nagpal R
    Life Sci; 2023 Jun; 322():121685. PubMed ID: 37044173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota, obesity and diabetes.
    Patterson E; Ryan PM; Cryan JF; Dinan TG; Ross RP; Fitzgerald GF; Stanton C
    Postgrad Med J; 2016 May; 92(1087):286-300. PubMed ID: 26912499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gut-liver axis at the frontier of host-microbial interactions.
    Brandl K; Kumar V; Eckmann L
    Am J Physiol Gastrointest Liver Physiol; 2017 May; 312(5):G413-G419. PubMed ID: 28232456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microbiome Disturbances and Autism Spectrum Disorders.
    Rosenfeld CS
    Drug Metab Dispos; 2015 Oct; 43(10):1557-71. PubMed ID: 25852213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The gut microbiota and the metabolic health of the host.
    Joyce SA; Gahan CG
    Curr Opin Gastroenterol; 2014 Mar; 30(2):120-7. PubMed ID: 24468803
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut microbiota in chronic kidney disease.
    Cigarran Guldris S; González Parra E; Cases Amenós A
    Nefrologia; 2017; 37(1):9-19. PubMed ID: 27553986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The human microbiome and bile acid metabolism: dysbiosis, dysmetabolism, disease and intervention.
    Jones ML; Martoni CJ; Ganopolsky JG; Labbé A; Prakash S
    Expert Opin Biol Ther; 2014 Apr; 14(4):467-82. PubMed ID: 24479734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between Gut Microbiota, Gut Hyperpermeability and Obesity.
    Gasmi A; Mujawdiya PK; Pivina L; Doşa A; Semenova Y; Benahmed AG; Bjørklund G
    Curr Med Chem; 2021; 28(4):827-839. PubMed ID: 32693755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gut-organ axis: a microbial outreach and networking.
    Ahlawat S; Asha ; Sharma KK
    Lett Appl Microbiol; 2021 Jun; 72(6):636-668. PubMed ID: 32472555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.